featured
Efficacy of Once-Weekly Semaglutide vs Thrice-Daily Insulin Aspart as Add-On to Metformin and Insulin Glargine in Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial
Diabetes Obes Metab 2022 May 11;[EPub Ahead of Print], M Kellerer, MS Kaltoft, J Lawson, LL Nielsen, K Strojek, Ö Tabak, S JacobFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.